Cell-free DNA screening
for trisomy 13, 18 and 21

Healthcare Professional Space

Information for Healthcare Professionals

nouveau test trisomie 21 professionnels de sante FRADownload the information brochure

A test on fetal DNA circulating in the maternal blood

Testing of the fetal DNA circulating in the maternal blood is used since many years in the follow-up of pregnancies, especially for fetal sex determination in the context of genetic diseases linked to chromosome X and for fetal Rhesus D determination in case of feto-maternal incompatibilities.

A prenatal test

The cell‐free DNA screening for trisomy 13,18 and 21 is a prenatal test performed on a simple blood sampling from the mother.

It enables, as early as the 10th week of gestation in pregnant women, to determine if the fetus carries a trisomy 21 or another aneuploidy of type 13 or 18.
Its sensitivity and specificity are greater than 99% for trisomies 13, 18 and 21.
When applied to the management of patients with increased risk of trisomy 21 without signs at ultrasound scan, it dramatically reduces (around 95%) the number of invasive procedures (amniocentesis or biopsy of chorionic villi) resulting into iatrogenic miscarriages in around 1% of cases.
In case of positive result of the Cell‐free DNA screening for trisomy 13,18 and 21, a fetal karyotype for confirmation will be performed.

Strategy for diagnosis of Down Syndrome

 Strategy diagnosis down syndrome EN


Print Top of page
11
09
2016

More than 25 000 tests

To date, more than 25 000 pregnant women received a...

Read more
04
07
2016

More than 9.600 tests

To date, more than 9.600 pregnant women from entire France...

Read more

Agenda

Scientific evening

December 2018
M T W T F S S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31